2/18
09:11 am
alxo
ALX Oncology to Host Virtual R&D Day on March 5, 2025 [Yahoo! Finance]
Medium
Report
ALX Oncology to Host Virtual R&D Day on March 5, 2025 [Yahoo! Finance]
2/18
08:00 am
alxo
ALX Oncology to Host Virtual R&D Day on March 5, 2025
Medium
Report
ALX Oncology to Host Virtual R&D Day on March 5, 2025
1/27
11:10 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at UBS Group AG from $4.00 to $2.20. They now have a "buy" rating on the stock.
Medium
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at UBS Group AG from $4.00 to $2.20. They now have a "buy" rating on the stock.
1/24
10:33 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
1/24
08:02 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at HC Wainwright from $25.00 to $5.00. They now have a "buy" rating on the stock.
Medium
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its price target lowered by analysts at HC Wainwright from $25.00 to $5.00. They now have a "buy" rating on the stock.
1/23
11:41 am
alxo
ALX Oncology stock falls 16% amid Phase 2 data update [Seeking Alpha]
Medium
Report
ALX Oncology stock falls 16% amid Phase 2 data update [Seeking Alpha]
1/23
08:00 am
alxo
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
Medium
Report
ALX Oncology Presents Positive Updated Data from ASPEN-06 Phase 2 Trial Demonstrating Evorpacept Generates Strong Response and Durable Clinical Benefit in Patients with HER2-Positive Gastric Cancer
1/23
07:09 am
alxo
How Nike's new CEO plans to rebound from its worst year ever [Fortune]
High
Report
How Nike's new CEO plans to rebound from its worst year ever [Fortune]
1/22
04:01 pm
alxo
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
Medium
Report
ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules
1/22
09:00 am
alxo
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
Medium
Report
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
1/22
09:00 am
alxo
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
Medium
Report
Oncology's Best Minds Set to Meet at Upcoming 2025 ASCO Gastrointestinal Cancers Symposium
1/22
08:00 am
alxo
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors
Medium
Report
ALX Oncology Announces Further Additions to Leadership Team and Board of Directors, Appointing Harish Shantharam as Chief Financial Officer and Adding Barbara Klencke and Chris Takimoto to Board of Directors
1/21
06:26 pm
alxo
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI [Yahoo! Finance]
Medium
Report
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI [Yahoo! Finance]
1/21
05:00 pm
alxo
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
Medium
Report
ALX Oncology to Host Virtual Company Event Highlighting Updated Data from ASPEN-06 Phase 2 Trial Presented at 2025 ASCO GI
1/7
08:35 am
alxo
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
Low
Report
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference [Yahoo! Finance]
1/7
08:00 am
alxo
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
ALX Oncology to Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/19
09:07 am
alxo
Yahoo Finance [Yahoo! Finance]
High
Report
Yahoo Finance [Yahoo! Finance]
12/19
07:42 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $2.00 price target on the stock, down previously from $12.00.
High
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) was downgraded by analysts at Jefferies Financial Group Inc. from a "buy" rating to a "hold" rating. They now have a $2.00 price target on the stock, down previously from $12.00.
12/18
09:19 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Low
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
12/18
08:14 am
alxo
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium [Yahoo! Finance]
Low
Report
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium [Yahoo! Finance]
12/18
08:07 am
alxo
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Low
Report
ALX Oncology Holdings Inc. (NASDAQ: ALXO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
12/18
08:00 am
alxo
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
Low
Report
ALX Oncology to Present Updated Results from Phase 2 ASPEN-06 Clinical Trial of Evorpacept in Patients with HER2-Positive Gastric Cancer in Oral Presentation at 2025 ASCO Gastrointestinal Cancers Symposium
12/12
08:17 am
alxo
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 [Yahoo! Finance]
Medium
Report
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 [Yahoo! Finance]
12/12
08:00 am
alxo
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
Low
Report
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024
12/10
09:07 am
alxo
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer [Yahoo! Finance]
Medium
Report
ALX Oncology Announces New Data Demonstrating Evorpacept in Combination with Zanidatamab Generates Promising Antitumor Activity in Advanced Breast Cancer [Yahoo! Finance]